In DLBCL, PBMC stimulation in the presence of idelalisib also resulted in less production of IFNy, but more IL-2 and a less differentiated phenotype as measured by CD27 and CD28 expression [196], which might be beneficial. The gene discussed is IL2; the disease is diffuse large B-cell lymphoma.